BIC has signed a joint position paper stressing that the EU Biotech Act II must be a dedicated and globally ambitious piece of legislation capable of delivering biomanufacturing scale-up and market deployment across Europe.
Europe remains the only major global region without a dedicated biomanufacturing initiative. At a time when global competitors such as the United States, India and China are prioritising biomanufacturing at the highest strategic level, the signatories underline the urgent need for a strong EU framework to strengthen Europe’s competitiveness, build resilient value chains and create high-quality employment.
While existing actions, including the EU Biotech Act Part I, have helped boost innovation, a critical gap remains in translating innovation into industrial-scale production across sectors. A focused EU Biotech Act II is therefore essential to ensure that European innovation leads to manufacturing capacity, market deployment and long-term industrial growth within Europe.
BIC will continue working with industry organisations and stakeholders to support a shared vision for Europe’s industrial future and to ensure that biomanufacturing plays its full role in delivering sustainable growth, resilience and strategic autonomy for Europe.
BIC Executive Director Philippe Mengal said, “A Biotech Act II on biomanufacturing; covering all sub-sectors of the bio-based industries is key for the EU’s competitiveness and for EU autonomy. Europe need a supportive, simplified and stable regulatory framework to develop and deploy biorefineries in Europe at large scale rather than watching it being delivered elsewhere, creating jobs outside Europe. It is needed to ensure visibility and predictability for EU industry and investors."
